39086659|t|The role of autophagy in the progression of HIV infected cardiomyopathy.
39086659|a|Although highly active antiretroviral therapy (HAART) has changed infection with human immunodeficiency virus (HIV) from a diagnosis with imminent mortality to a chronic illness, HIV positive patients who do not develop acquired immunodeficiency syndrome (AIDs) still suffer from a high rate of cardiac dysfunction and fibrosis. Regardless of viral load and CD count, HIV-associated cardiomyopathy (HIVAC) still causes a high rate of mortality and morbidity amongst HIV patients. While this is a well characterized clinical phenomena, the molecular mechanism of HIVAC is not well understood. In this review, we consolidate, analyze, and discuss current research on the intersection between autophagy and HIVAC. Multiple studies have linked dysregulation in various regulators and functional components of autophagy to HIV infection regardless of mode of viral entry, i.e., coronary, cardiac chamber, or pericardial space. HIV proteins, including negative regulatory factor (Nef), glycoprotein 120 (gp120), and transactivator (Tat), have been shown to interact with type II microtubule-associated protein-1 beta light chain (LC3-II), Rubiquitin, SQSTM1/p62, Rab7, autophagy-specific gene 7 (ATG7), and lysosomal-associated membrane protein 1 (LAMP1), all molecules critical to normal autophagy. HIV infection can also induce dysregulation of mitochondrial bioenergetics by altering production and equilibrium of adenosine triphosphate (ATP), mitochondrial reactive oxygen species (ROS), and calcium. These changes alter mitochondrial mass and morphology, which normally trigger autophagy to clear away dysfunctional organelles. However, with HIV infection also triggering autophagy dysfunction, these abnormal mitochondria accumulate and contribute to myocardial dysfunction. Likewise, use of HAART, azidothymidine and Abacavir, have been shown to induce cardiac dysfunction and fibrosis by inducing abnormal autophagy during antiretroviral therapy. Conversely, studies have shown that increasing autophagy can reduce the accumulation of dysfunctional mitochondria and restore cardiomyocyte function. Interestingly, Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, has also been shown to reduce HIV-induced cytotoxicity by regulating autophagy-related proteins, making it a non-antiviral agent with the potential to treat HIVAC. In this review, we synthesize these findings to provide a better understanding of the role autophagy plays in HIVAC and discuss the potential pharmacologic targets unveiled by this research.
39086659	44	71	HIV infected cardiomyopathy	Disease	MESH:D015658
39086659	139	182	infection with human immunodeficiency virus	Disease	MESH:D015658
39086659	184	187	HIV	Disease	MESH:D015658
39086659	252	255	HIV	Disease	MESH:D015658
39086659	265	273	patients	Species	9606
39086659	293	327	acquired immunodeficiency syndrome	Disease	MESH:D000163
39086659	329	333	AIDs	Disease	MESH:D000163
39086659	368	387	cardiac dysfunction	Disease	MESH:D006331
39086659	392	400	fibrosis	Disease	MESH:D005355
39086659	431	433	CD	Disease	MESH:D003424
39086659	441	470	HIV-associated cardiomyopathy	Disease	MESH:D016263
39086659	472	477	HIVAC	Disease	MESH:D016263
39086659	539	542	HIV	Disease	MESH:D015658
39086659	543	551	patients	Species	9606
39086659	635	640	HIVAC	Disease	MESH:D016263
39086659	777	782	HIVAC	Disease	MESH:D016263
39086659	891	904	HIV infection	Disease	MESH:D015658
39086659	995	998	HIV	Disease	MESH:D015658
39086659	1053	1069	glycoprotein 120	Gene	3700
39086659	1071	1076	gp120	Gene	3700
39086659	1218	1224	SQSTM1	Gene	8878
39086659	1225	1228	p62	Gene	8878
39086659	1230	1234	Rab7	Gene	338382
39086659	1236	1261	autophagy-specific gene 7	Gene	10533
39086659	1263	1267	ATG7	Gene	10533
39086659	1274	1313	lysosomal-associated membrane protein 1	Gene	3916
39086659	1315	1320	LAMP1	Gene	3916
39086659	1367	1380	HIV infection	Disease	MESH:D015658
39086659	1484	1506	adenosine triphosphate	Chemical	MESH:D000255
39086659	1508	1511	ATP	Chemical	MESH:D000255
39086659	1528	1551	reactive oxygen species	Chemical	MESH:D017382
39086659	1553	1556	ROS	Chemical	MESH:D017382
39086659	1563	1570	calcium	Chemical	MESH:D002118
39086659	1714	1727	HIV infection	Disease	MESH:D015658
39086659	1824	1846	myocardial dysfunction	Disease	MESH:D006331
39086659	1872	1886	azidothymidine	Chemical	MESH:D015215
39086659	1891	1899	Abacavir	Chemical	MESH:C106538
39086659	1927	1946	cardiac dysfunction	Disease	MESH:D006331
39086659	1951	1959	fibrosis	Disease	MESH:D005355
39086659	2188	2197	Rapamycin	Chemical	MESH:D020123
39086659	2201	2230	mammalian target of rapamycin	Gene	2475
39086659	2232	2236	mTOR	Gene	2475
39086659	2279	2282	HIV	Disease	MESH:D015658
39086659	2291	2303	cytotoxicity	Disease	MESH:D064420
39086659	2406	2411	HIVAC	Disease	MESH:D016263
39086659	2523	2528	HIVAC	Disease	MESH:D016263
39086659	Association	MESH:D015658	8878
39086659	Negative_Correlation	MESH:D020123	2475
39086659	Positive_Correlation	MESH:D015215	MESH:D006331
39086659	Association	MESH:D017382	MESH:D015658
39086659	Positive_Correlation	MESH:C106538	MESH:D006331
39086659	Association	MESH:D015658	3916
39086659	Positive_Correlation	MESH:D015215	MESH:D005355
39086659	Association	MESH:D000255	MESH:D015658
39086659	Negative_Correlation	MESH:D020123	MESH:D064420
39086659	Association	MESH:D015658	338382
39086659	Positive_Correlation	MESH:C106538	MESH:D005355
39086659	Association	MESH:D015658	10533
39086659	Association	MESH:D002118	MESH:D015658
39086659	Association	MESH:D015658	3700

